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Angiotensin-converting enzyme (ACE) activity and polymorphism contribute significantly to the prognosis of patients with
cardiomyopathy. The aim of this study was to determine the activity and type of ACE polymorphism in patients with familial and
nonfamilial hypertrophic cardiomyopathy (HCM) and to correlate these with echocardiographic measurements (echo-Doppler).
We studied 136 patients (76 males) with HCM (69 familial and 67 nonfamilial cases). Mean age was 41 ± 17 years. DNA was
extracted from blood samples for the polymerase chain reaction and the determination of plasma ACE levels. Left ventricular
mass, interventricular septum, and wall thickness were measured. Mean left ventricular mass index, interventricular septum and
wall thickness in familial and nonfamilial forms were 154 ± 63 and 174 ± 57 g/m2 (P = 0.008), 19 ± 5 and 21 ± 5 mm (P = 0.02),
and 10 ± 2 and 12 ± 3 mm (P = 0.0001), respectively. ACE genotype frequencies were DD = 35%, ID = 52%, and II = 13%. A
positive association was observed between serum ACE activity and left ventricular mass index (P = 0.04). Logistic regression
showed that ACE activity was twice as high in patients with familial HCM and left ventricular mass index ≥190 g/m2 compared
with the nonfamilial form (P = 0.02). No other correlation was observed between ACE polymorphisms and the degree of
myocardial hypertrophy. In conclusion, ACE activity, but not ACE polymorphisms, was associated with the degree of myocardial
hypertrophy in the patients with HCM.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a complex ge-
netic disease with broad phenotypic heterogeneity result-
ing in a range of outcomes and prognoses (1,2). The
angiotensin-converting enzyme (ACE) gene deletion/in-
sertion polymorphism, which has three distinct genotypes
(II, ID, and DD) (1,3-5), is an important modifying factor of
HCM. The ACE DD genotype is more common than the ID
or II genotypes in patients with the familial form of HCM and
has been associated with the severity of left ventricular
hypertrophy and with interventricular septal, apical, and
wall thickness (6-8).
ACE converts angiotensin I to angiotensin II (5), an
important mediator in secondary myocardial hypertrophy,
postmyocardial infarction remodeling, and heart failure.
Although blood levels of angiotensin II are not increased in
HCM patients, a relation seems to exist between HCM
phenotype and ACE genetic polymorphism (9). In addition,
angiotensin II has well-established profibrotic effects, and
studies have suggested myocardial fibrosis as another
important cause of diastolic dysfunction in HCM (10,11).
We have also shown that losartan, a renin-angiotensin-
aldosterone system (RAAS) blocker, leads to clinical im-
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provement evaluated by functional class (NYHA), to a
decrease in plasma levels of B-type natriuretic peptide,
and to improved diastolic dysfunction in HCM patients
(12). Nevertheless, there are no reports in the literature
correlating ACE activity with myocardial hypertrophy in
patients with familial and nonfamilial forms of HCM.
The aim of this study was to determine ACE polymor-
phism and its plasma activity in patients with the familial
and nonfamilial forms of HCM and to correlate it with the
echocardiographic measures.
Material and Methods
We selected 136 consecutive patients with HCM from
the Cardiomyopathy Unit, Hospital das Clínicas, Faculda-
de de Medicina, Universidade de São Paulo/Heart Institute
(InCor). Sixty-nine patients presented the familial form and
67 the nonfamilial form of HCM. Mean age was 41 ± 17
years, and 76 patients were males. All patients signed an
informed consent form. The study was approved by the
Ethics Committee of Hospital das Clínicas, Faculdade de
Medicina, Universidade de São Paulo (#360/98).
The inclusion criteria were diastolic septum thickness
>15 mm in HCM patients and >13 mm in their relatives (on
echocardiography), and absence of left ventricular dilation
(13). The exclusion criteria were use of ACE inhibitors and/
or angiotensin receptor blockers, hypertension (blood pres-
sure ≥139/89 mmHg) (14) and other comorbidities known
to influence septum thickness. The familial form was char-
acterized by a history of sudden death and a diagnosis of
HCM among third-degree relatives younger than 40 years
of age. Patients who met none of these criteria were
classified as presenting nonfamilial HCM (15).
Echocardiographic studies were performed using M-
mode echocardiography according to the recommenda-
tions of the American Society of Echocardiography. The
following parameters were determined: left ventricular mass,
interventricular septum, and wall thickness (Acuson Se-
quoia 512 unit, USA, and a 2-3.5-MHz multifrequency
transducer) (16). Left ventricular mass index was obtained
using the formula “mass/BMI (g/m2)”, where mass (g) = 0.8
{1.04[(Dd + PW + IVS)3 - (Dd)3]} + 0.6 (Dd = left ventricular
diastolic diameter, PW = posterior wall thickness, IVS =
interventricular septal thickness, in cm), and body mass
index (m2) = weight0.425 x height0.725 x 0.00718 (17,18). The
echocardiographer was blind to the objective of the study.
Venous blood was collected into tubes containing EDTA
(disodium salt) for the isolation of peripheral blood leuko-
cytes. Genomic DNA was extracted from these cells by a
standard method and amplified by the polymerase chain
reaction (19).
Serum ACE activity was determined by the method
described by Alves et al. (20), which is based on the use of
a fluorescent peptide (Abz-FRK (Dnp) P-OH) hydrolyzed
with high affinity by ACE (Kcat/Km = 45.4/s). ACE activity
is reported as fluorescence units (FU)/mg of protein, or FU/
mL of serum (1 m FU = nmol of Abz-FRK (Dnp) P-OH
hydrolyzed per min).
Statistical analysis
Left ventricular mass was stratified into quintiles. Quali-
tative variables are reported as absolute frequencies (n)
and percentages (%). The association of these variables
with left ventricular mass index ≥190 g/m2 was determined
by the χ2 test. The association between echocardiographic
measures and ACE polymorphism and activity was deter-
mined by the Spearman test. Quantitative variables are
reported as means ± SD or as minimum and maximum
values. Mean values were compared by the Student t-test.
Variables that were statistically significant in univariate
analysis were used to adjust the logistic regression model.
A P value of ≤0.05 was considered to be significant (21).
Results
The distribution of ACE gene polymorphisms was as
follows: DD was observed in 47 patients (35%), ID in 71
(52%) patients, and II in 18 (13%) patients. Table 1 de-
scribes the main clinical data for the patients studied.
Table 2 shows the mean left ventricular mass indexes
(P = 0.008), interventricular septal thickness (P = 0.02) and
wall thickness (P = 0.0001) in familial and nonfamilial
HCM.
Table 1. Clinical data of patients with familial and nonfamilial
hypertrophic cardiomyopathy (HCM).
Variables Familial HCM Nonfamilial HCM
 (N = 69)  (N = 67)
Age (years) 38 ± 18 43 ± 7
Gender
Male 35 (51%) 41 (61%)
Female 34 (49%) 26 (39%)
Functional class (NYHA)
I 35 (51%) 38 (57%)
II 29 (42%) 20 (30%)
III 4 (6%) 8 (12%)
IV 1 (1%) 1 (1%)
Data are reported as means ± SD for age and number of patients
with percent of group in parentheses for all other variables. NYHA:
New York Heart Association functional classification of heart fail-
ure. There were no statistical differences between groups for all
parameters (age: nonpaired t-test; proportions: chi-square test).
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Mean ACE activity in the familial and nonfamilial forms
was 56,414 ± 19,236 and 55,085 ± 22,634 FU/mL, respec-
tively (P = 0.71). No correlation was found between ACE
polymorphism and degree of myocardial hypertrophy. ACE
activity was associated with left ventricular mass index (P
= 0.04).
A logistic regression curve showed that ACE activity
was twice as high in familial HCM patients with a left
ventricular mass index ≥190 g/m2 compared to patients
with the nonfamilial form (Figure 1; r = 0.766; P = 0.02).
ACE activity was not correlated with either interventricular
septal thickness (P = 0.08) or wall thickness (P = 0.18).
Discussion
The present results indicate that there are no differ-
ences between the familial and nonfamilial forms of HCM
regarding ACE insertion/deletion polymorphism.
Marian et al. (22) observed that the ACE D allele was
more frequent in affected relatives of HCM patients than in
unaffected relatives. They also observed that the DD geno-
type was more frequent in HCM patients, especially in
those with a family history of sudden death. Yoneya et al.
(7) concluded that the ACE D allele is a genetic factor for
cardiac hypertrophy and that the ACE DD genotype is a
potential genetic marker. They demonstrated that the fre-
quency of the D allele in nonfamilial forms was higher than
that in the familial form and controls. However, we showed
that the D allele and DD genotype had no influence on
hypertrophy.
As also observed here, Yamada et al. (23) reported
that ACE polymorphism was not related to HCM in Japa-
nese patients, and that variants of this polymorphism did
not contribute to the genesis or progression of the disease.
When compared with previous studies, Yamada et al. (23)
Figure 1. Logistic regres-
sion analysis of ventricular
mass index ≥190 g/m2 vs
angiotensin-converting en-
zyme (ACE) activity in pa-
tients with familial and
nonfamilial hypertrophic
cardiomyopathy. FU = flu-
orescence units.
Table 2. Mean left ventricular mass index (LVMI), interventricu-
lar septum (IVS), posterior wall (PW), and left atrium (LA) in
patients with familial and nonfamilial hypertrophic cardiomyopa-
thy (HCM).
Variables Familial HCM Nonfamilial HCM
(N = 67) (N = 67)
LVMI (g/m2) 154 ± 63 174 ± 57*
IVS (mm) 19 ± 5 21 ± 5*
PW (mm) 10 ± 2 12 ± 3*
LA (mm) 42 ± 8 44 ± 9
Data are reported as means ± SD. *P < 0.05 compared to familial
HCM (nonpaired t-test).
found a different distribution of ACE genotypes: in 71
patients with the nonfamilial form of HCM, they identified
11% with DD, 45% with ID, and 44% with II, a distribution
similar to that observed in control subjects (14% with DD,
45% with ID, and 41% with II).
Lopez-Haldon et al. (24) studied the effect of ACE
polymorphism in patients with the familial and nonfamilial
forms of HCM and concluded that the D allele and DD
genotype were associated with a predisposition to hyper-
trophy. Doolan et al. (25) investigated the progression of
left ventricular hypertrophy and the ACE polymorphism in
HCM patients and demonstrated that progression of left
ventricular hypertrophy is higher in the presence of the DD
genotype than in other genotypes. Thus, the DD genotype
could be an important predictor of disease progression in
HCM. In the present study, however, we did not find a
significant difference between genotypes and alleles in the
familial and nonfamilial forms of HCM and between pa-
tients with different degrees of myocardial hypertrophy
determined by echocardiographic parameters, in agree-
ment with the observations made by Rai et al. (26).
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Perkins et al. (15) evaluated ACE polymorphism ac-
cording to the genesis and progression of the disease in
patients with the nonfamilial form of HCM. They demon-
strated that patients with the DD genotype had a higher
level of ACE and angiotensin II and, consequently, an
increase in hypertrophy and fibrosis, and concluded that
the DD genotype influences the degree of left ventricular
hypertrophy and the severity of the disease.
Other findings indicate that HCM can be considered a
polygenic disease with different degrees of penetrance
and mutations, leading to different genotypes and pheno-
typic expression. In Brazil, this fact could be explained by
the high incidence of miscegenation throughout our history
(27). Tesson et al. (28) showed that the ACE genotype can
influence the phenotypic expression of hypertrophy, and
that this influence depends on mutation, which supports
the concept of multiple modifier genes in patients with the
familial form of HCM. Likewise, Lechin et al. (4) showed
that the ACE gene modifies the phenotypic expression of
hypertrophy in HCM patients. In addition, Ortlepp et al.
(29), who studied the genetic polymorphism of the RAAS
associated with the expression of left ventricular hypertro-
phy in HCM, observed several polymorphisms that influ-
enced both the prevalence and the degree of left ventricu-
lar hypertrophy caused by mutation in the cardiac myosin-
binding protein C gene.
Our study showed higher left ventricular mass index
and increased interventricular septum and wall thickness
hypertrophy in patients with the nonfamilial form of HCM
compared with patients with the familial form. In addition,
we observed that patients with higher levels of ACE activity
had a large left ventricular mass index. To our knowledge,
this is the first report of ACE activity in patients with HCM.
Angiotensin I is converted by ACE into angiotensin II,
which is an important mediator in myocardial hypertrophy
and fibrosis. Masutomo et al. (30), in an experimental
study of HCM using losartan, demonstrated a decrease in
left ventricular collagen concentration. Lim et al. (31) ob-
served similar results in an experimental study using the
troponin T gene in a transgenic mouse model of human
HCM. These investigators observed that losartan treat-
ment decreased myocardial fibrosis and the expression of
collagen type I.
The present study allowed us to individualize and
select HCM patients with higher levels of ACE and conse-
quently a large left ventricular mass index for treatment
using RAAS blockers. A logistic regression curve showed
that in patients with familial HCM and left ventricular mass
index ≥190 g/m2 ACE activity was twice that of nonfamilial
form patients (P = 0.02). For this reason, we believe that
ACE antagonism could be different in the familial and
nonfamilial forms of HCM. More studies are necessary to
evaluate this hypothesis.
We observed an association between ACE activity and
left ventricular mass index. Otherwise, there was no corre-
lation between the ACE polymorphism and the degree of
myocardial hypertrophy.
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